The Genomic Health Oncotype DX Prostate Cancer Assay
shared by bkohlmeier on Feb 25
240
views
0
faves
0
comments
Prostate cancer screenings occur in 23 million men each year, with 250,000 being diagnosed with the affliction. In less severe cases, patients are quick to receive immediate treatment despite the fact...
that only 3% are likely to have a prostate cancer recurrence. Genomic Health is developing a test for prostate cancer patients, called the Oncotype DX Prostate Cancer Test (assay), which will help determine how aggressive the prostate cancer is and aides doctors and patients in forming an individualized course of treatment. Read more: http://bit.ly/ProstateOncotypeDX
Source
http://www.y...omichealthCategory
HealthGet a Quote